Current and ongoing progress in the therapy for resectable esophageal cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Esophageal cancer treatment has seen recent surgical advancements.
• Neoadjuvant chemoradiotherapy is a standard approach for resectable esophageal cancer, irrespective of histology.
• Pathologic response after neoadjuvant therapy predicts patient outcomes.

Purpose of the Study:

• To review current surgical and neoadjuvant treatment standards for resectable esophageal cancer.
• To discuss the role of molecularly targeted agents in esophageal cancer therapy.
• To highlight the translational research embedded in ongoing clinical trials for esophageal cancer.

Main Methods:

• Review of recent literature on surgical techniques for esophageal cancer.
• Analysis of the role of neoadjuvant chemoradiotherapy in resectable esophageal cancer.
• Discussion of emerging targeted therapies and clinical trial designs.

Main Results:

• Surgical techniques for esophageal cancer have advanced.
• Neoadjuvant chemoradiotherapy is a widely adopted standard of care.
• Pathologic response is a key surrogate marker for treatment efficacy.
• Novel targeted agents are being investigated for personalized esophageal cancer treatment.

Conclusions:

• Combined-modality treatment, including neoadjuvant chemoradiotherapy and surgery, is central to managing resectable esophageal cancer.
• Translational research in clinical trials aims to identify patient subgroups who will benefit from targeted therapies.
• Future directions involve integrating targeted agents with standard approaches to improve outcomes in esophageal cancer.